Navigation Links
New Cancer Drug Fights Tumors in Those With BRCA Mutations

Olaparib prevents malignant cells from repairing themselves, researchers say ,,

WEDNESDAY, June 24 (HealthDay News) -- A new cancer drug called olaparib worked well in an early clinical trial against breast, ovarian and prostate cancers in individuals who were genetically vulnerable to developing these malignancies.

Women who carry BRCA1 and BRCA2 gene mutations are susceptible to developing breast and ovarian cancer, and among men these mutations are related to an increased risk for prostate cancer, the British researchers noted.

Olaparib works differently than other cancer drugs in that it blocks Poly(ADP-ribose) polymerase (PARP), a protein involved in DNA repair. Healthy cells use PARP to repair themselves, but cancer cells do the same, the scientists explained.

"This is an entirely new class of drugs," said Dr. J. Dirk Iglehart, from the department of surgery at Brigham and Women's Hospital and the department of cancer biology at the Dana-Farber Cancer Institute in Boston, and co-author of an accompanying journal editorial.

When you disable PARP, you prevent the cell from repairing itself, he said, and cancer cells that are deficient in BRCA are much more sensitive to this effect. "When you inhibit PARP, they can't stand it," Iglehart explained.

The report is published online June 24 in the New England Journal of Medicine.

In a phase 1 trial, led by Dr. Johann S. de Bono, from the Institute of Cancer Research at the Royal Marsden NHS Foundation Trust in Sutton, U.K., the scientists treated 60 men and women who were carriers of the BRCA1 or BRCA2 mutations, or had a family history of BRCA-related cancer, with olaparib. All of the patients had either breast, ovarian, prostate, colorectal, melanoma, sarcoma or other cancers.

In this group, there were only a few adverse side effects and they were easily reversed by lowering the dose of the drug, the study noted.

Next, de Bono's team tried the drug on a smaller group of patients, all of whom were confirmed carriers of the BRCA1 or BRCA2 mutation. Those patients received 200 milligrams of olaparib twice a day.

The researchers found that olaparib was absorbed quickly, was eliminated from the body quickly, and had mild side effects. In addition, among people with the BRCA mutations the drug shrunk tumors in breast, ovarian and prostate cancer.

"Olaparib has few of the adverse effects of conventional chemotherapy, inhibits PARP, and has anti-tumor activity in cancer associated with the BRCA1 and BRCA2 mutation," the team concluded.

Iglehart thinks that combining a PARP inhibitor with chemotherapy drugs that damage DNA might make the drug even more effective. "You might then push cancers over the cliff that would be only susceptible to a PARP inhibitor," he said.

In addition, "PARP inhibitors may be used for tumors that Herceptin or tamoxifen are totally incapable of treating," he said. "That's true for ovarian cancer, too. There is nothing to treat that disease."

Two other trials of PARP inhibitors, which were reported on during the American Society of Clinical Oncology annual meeting in June, also found that they were effective in treating breast cancer.

In one trial where PARP inhibitors were combined with standard chemotherapy, there was almost a doubling of survival -- from 5.7 months with chemo alone to 9.2 months when the PARP inhibitor BSI-201 was added, as well as about a 60 percent reduction in the risk of dying from the disease. There were also no additional side effects.

The second PARP inhibitor trial involved 54 women with advanced breast cancer who carried the BRCA mutations. In this trial, 41 percent of patients saw their tumors disappear. There was a slightly lower response rate in the lower-dose group. Mild nausea and fatigue were the most common side effects.

"The drugs are given orally, and it still remains a question as to whether the drugs' benefits will extend beyond this narrow patient population," noted Dr. Eric Weiner, chief of women's cancers at the Dana-Farber Cancer Institute.

"These two studies are very exciting," Dr. Kelly Marcom, a breast oncologist with Duke Comprehensive Cancer Center and director of the Duke Hereditary Cancer Clinic in Durham, N.C., said. "It speaks to a really clever understanding of the biology of the cancer."

More information

For more information on BRCA1 and BRCA2 cancer, visit the U.S. National Cancer Institute.

SOURCES: J. Dirk Iglehart, M.D., department of surgery, Brigham and Women's Hospital, and the department of cancer biology, Dana-Farber Cancer Institute, Boston; Eric Weiner, M.D., chief, women's cancers, Dana-Farber Cancer Institute, Boston; Kelly Marcom, M.D., breast oncologist, Duke Comprehensive Cancer Center, and director, Duke Hereditary Cancer Clinic, Durham, N.C.; June 24, 2009, New England Journal of Medicine, online

Copyright©2009 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Study pinpoints novel cancer gene and biomarker
2. SpectraScience Secures Distribution for WavSTAT(R) Cancer Diagnosis System in Spain
3. Wildlife faces cancer threat
4. Veran Medical Enables Breakthrough 4D Navigation to Cancer Lesions at University of Virginia Hospital
5. Study Finds Skin Cancer Rates Higher Among Athletes
6. Bariatric Surgery Cuts Cancer Risk for Women
7. Obesity While Young Boosts Pancreatic Cancer Risk
8. Being overweight, obese during early adulthood associated with greater risk of pancreatic cancer
9. Children's National Medical Center Honors The Children's Cancer Foundation for Commitment to Area Kids
10. Schizophrenia Linked to Higher Risk of Dying From Cancer
11. Lung Cancer Alliance Hails Signing of Tobacco Control Legislation Into Law; Urges Action on Lung Cancer
Post Your Comments:
Related Image:
New Cancer Drug Fights Tumors in Those With BRCA Mutations
(Date:11/27/2015)... ... November 27, 2015 , ... Intellitec Solutions ... SL User Group (MSDSLUG). Recognized as Microsoft’s official group for end users of ... SL software users, partners, industry experts and representatives. Intellitec Solutions’ membership status demonstrates ...
(Date:11/27/2015)... Los Angeles, CA (PRWEB) , ... November 27, 2015 , ... ... the Commission on Accreditation of Allied Health Education Programs (CAAHEP) awarded accreditation to its ... exclusive list of CAAHEP accredited colleges, as only one of twelve colleges and universities ...
(Date:11/27/2015)... ... ... Indosoft Inc., developer and distributor of the world-class Asterisk ... Term Support) into its Q-Suite 5.10 product line. , Making the change to ... of Asterisk that will receive not only security fixes, but feature and bug ...
(Date:11/26/2015)... ... 2015 , ... Somu Sivaramakrishnan announced today that he joined ... offers travelers, value and care based Travel Services, including exclusive pricing on a ... cabin upgrades and special amenities such as, shore excursions, discounted fares, travel gifts ...
(Date:11/26/2015)... Mass. (PRWEB) , ... November 26, 2015 , ... ... thorough second medical opinion process, participated in the 61st annual Employee Benefits Conference. ... Plans and took place Sunday, November 8th through Wednesday, November 11th, 2015. The ...
Breaking Medicine News(10 mins):
(Date:11/26/2015)... , November 26, 2015 ... Juntendo universitetssjukhus ser potential att använda SyMRI ... (MR-bilder) för patienter med multipel skleros ... forskningsavtal med SyntheticMR AB för att kunna ... på sjukhuset. Med SyMRI kan man generera ...
(Date:11/26/2015)... India , November 26, 2015 ... --> adds ... Report" and "Investigation Report on China ... and 2021 forecasts data and information ... . ...
(Date:11/26/2015)... 2015 ) ... "Radioimmunoassay Market by Type (Reagents & Kits, ... Clinical Diagnostic Labs), Application (Research, Clinical Diagnostics), ... report to their offering. --> ... of the "Radioimmunoassay Market by Type ...
Breaking Medicine Technology: